In Gide cohort, the 41 melanoma patients treated with PD1-CTLA4 combination inhibitor with high TMEscore had significantly better OS and PFS than other patients (P = 0.0012, HR = 2.387, CI = [1.22, 6.77] for OS; P = 0.0063, HR = 1.31, CI = [1.31, 6.15] for PFS, respectively, Figure 6A, 6B). Here, PDCD1 is linked to melanoma.